Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis

Hawro, Marlena; Maurer, Marcus; Weller, Karsten; Maleszka, Romuald; Zalewska-Janowska, Anna; Kaszuba, Andrzej; Gerlicz-Kowalczuk, Zofia; Hawro, Tomasz

doi:10.1016/j.jaad.2016.10.040

Cited by 65 publications

(74 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with onychomycosis [12][13][14] and nail psoriasis [15] often feel embarrassed or stigmatized because of their disease. Such feelings are not unfounded, as shown by a recent online survey [14] , in which many respondents expressed reluctance to spend time with or be placed next to onychomycosis patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis

Piraccini

Starace²,

Toft³

2017

Dermatology

View full text Add to dashboard Cite

Introduction: Onychomycosis and nail psoriasis can be embarrassing to patients, so improving the appearance of affected nails should be one of the key short-term goals of treatment. Methods: An 8-week open-label multicenter study was conducted to assess whether K101-03, a marketed topical treatment containing propylene glycol, glycerol, urea, and lactic acid, could produce rapid cosmetic improvements in affected nails. Adult patients with a big toenail or thumbnail (the “target” nail) affected by onychomycosis (n = 72) or psoriasis (n = 34) or both (n = 1) applied K101-03 to their affected nails once a day for 8 weeks. During and after treatment, patients rated the overall appearance of their target nail on a 4-point scale. They also assessed whether thickening, discoloration, brittleness, and softness of the target nail had improved since baseline. Adverse events (AEs) that occurred between the first application of K101-03 and the end of treatment were recorded and categorized according to severity and relationship to K101-03. Results: After 8 weeks of K101-03 treatment, 92.2% of patients (95% confidence interval [CI] 87.06-97.40) reported at least some improvement in the target nail. After 1 week of treatment, 78.3% of patients with onychomycosis (95% CI 68.53-87.99) reported at least some improvement in the target nail, and 55.1% of them reported that discoloration of their target nail had improved. Three patients reported a total of 5 AEs, none of which were judged to be related to K101-03. Conclusions: In summary, K101-03 was well tolerated in patients with onychomycosis or nail psoriasis and rapidly improved their nails.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Onychomycosis [12][13][14] and nail psoriasis [15] can cause embarrassment, stigmatization, and other psychosocial problems. Patients would therefore benefit from treatments that produce rapid cosmetic improvements in affected nails.…”

Section: Introductionmentioning

confidence: 99%

Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis

Piraccini

Starace²,

Toft³

2017

Dermatology

View full text Add to dashboard Cite

show abstract

“…Patients with genital psoriasis experience impairments in physical activity, personal relationships, work and school, and emotions 25. Although these patients report stigmatization, two studies indicate that patients with genital involvement experience greater feelings of stigmatization than psoriasis patients without genital lesions,31,32 while one did not 33. Two other studies demonstrated that patients with genital psoriasis or genital discomfort experienced more depressive symptoms than patients without genital symptoms 6,26…”

Section: Symptomsmentioning

confidence: 99%

The impact of genital psoriasis on quality of life: a systematic review

Yang¹,

Beck²,

Sanchez³

et al. 2018

PTT

View full text Add to dashboard Cite

Psoriasis is a chronic immune-mediated inflammatory disease with significant medical and psychological comorbidities. In addition to having increased cardiovascular risk and mortality, psoriasis patients are more likely to be depressed, anxious, and endorse suicidal ideation than the general population. These patients often have low self-esteem and feel stigmatized due to their skin disease, which can prevent them from pursuing relationships, dating, and attending social activities. Up to 63% of adult psoriasis patients experience psoriatic lesions on their genital area during their lifetime, but often do not discuss these issues with their physicians due to embarrassment, stigmatization, or shyness about this sensitive location. However, psoriasis in sensitive areas, such as the genitals, may result in quality of life impairment greater than that of patients with psoriasis elsewhere on their body, particularly in respect to romantic relationships, intimacy, and sexual function. This article evaluates the current literature regarding the impact of genital psoriasis on the quality of life of affected patients.

show abstract

“…Psoriasis is a chronic, immune‐mediated, inflammatory skin disorder that affects approximately 0·1–3% of the general population worldwide . Given the visible nature of skin lesions, including those on the face, scalp, hands and nails, psoriasis is a significant physical and psychological burden to afflicted patients, decreases patient quality of life, and induces feelings of internalized stigma …”

Section: Introductionmentioning

confidence: 99%

Autoimmunity and autoimmune co‐morbidities in psoriasis

et al. 2018

View full text Add to dashboard Cite

SummaryPsoriasis is characterized by widespread scaly erythematous plaques that cause significant physical and psychological burdens for the affected individuals. Accelerated inflammation driven by the tumour necrosis factor-a/ interleukin-23/interleukin-17 axis is now known to be the major mechanism in the development of psoriasis. In addition, psoriasis has an autoimmune nature that manifests as autoreactive T cells and is comorbid with other autoimmune diseases, such as autoimmune bullous diseases, vitiligo, alopecia and thyroiditis. In this article, we review the recent topics on autoimmunity and autoimmune co-morbidities in psoriasis.

show abstract

Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis

Cited by 65 publications

References 25 publications

Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis

Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis

The impact of genital psoriasis on quality of life: a systematic review

Autoimmunity and autoimmune co‐morbidities in psoriasis

Contact Info

Product

Resources

About